SCUSF 0703: Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk

Service: Trial Number:
Principal Investigator: Conducted at:
Miller Children's & Women's Hospital Long Beach
Currently enrolling additional patients:
Age Range:
all ages

There is a risk for weight loss for children and adolescents treated for cancer, and an even greater risk of malnourishment in those already underweight. Not only the treatment, but cancer type may catalyze weight loss in some patients, wherein studies have shown that over 80% of patients with advanced disease experience cancer or treatment-related weight loss. This proposed double-blind study seeks to add an appetite stimulant cyproheptadine hydrochloride (CH), in pill form to at-risk children treated for cancer, and compare its effects to a placebo. In this way, researchers will be able to test the impact of CH to determine if the medicine prevents weight loss and malnutrition. Eligibility requirements include no history of unintended weight loss of over 5% body mass within the last 3 months as well as anorexia or bulimia during their lifetime, children with body mass indexes within the 95% percentile of their age, cannot be on MAO (monoamine oxidase) inhibitors used to treat depression, procarbazine, or some selective serotonin reuptake inhibitors used to treat depression, anxiety, and other mood disorders

MemorialCare Research Center Contact Form

For further information about this study or to express your interest in this study, please fill out and submit this form.
The email to associate with this registration.